Drugs / Senl-h19 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04792593 | Dec 2020 → Dec 2021 | — | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Senl-h19 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04792593 ↗ |
| Modality | Cell therapy | “Patients will be treated with Senl-h19 CAR-T cells” NCT04792593 ↗ |
| Target | CD19 | “CD19 CAR-T” NCT04792593 ↗ |